These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 19775474)
1. A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Lin SL; Yan LY; Liang XW; Wang ZB; Wang ZY; Qiao J; Schatten H; Sun QY Reprod Biol Endocrinol; 2009 Sep; 7():102. PubMed ID: 19775474 [TBL] [Abstract][Full Text] [Related]
2. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. Lin SL; Yan LY; Zhang XT; Yuan J; Li M; Qiao J; Wang ZY; Sun QY PLoS One; 2010 Feb; 5(2):e9013. PubMed ID: 20126312 [TBL] [Abstract][Full Text] [Related]
3. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway. Tong JS; Zhang QH; Wang ZB; Li S; Yang CR; Fu XQ; Hou Y; Wang ZY; Sheng J; Sun QY PLoS One; 2010 Nov; 5(11):e15408. PubMed ID: 21079811 [TBL] [Abstract][Full Text] [Related]
4. ER-α36, a novel variant of estrogen receptor α, is involved in EGFR-related carcinogenesis in endometrial cancer. Tu BB; Lin SL; Yan LY; Wang ZY; Sun QY; Qiao J Am J Obstet Gynecol; 2011 Sep; 205(3):227.e1-6. PubMed ID: 21684519 [TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity. Zhang X; Wang ZY Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601 [TBL] [Abstract][Full Text] [Related]
6. ER-α36 mediates estrogen-stimulated MAPK/ERK activation and regulates migration, invasion, proliferation in cervical cancer cells. Sun Q; Liang Y; Zhang T; Wang K; Yang X Biochem Biophys Res Commun; 2017 Jun; 487(3):625-632. PubMed ID: 28435071 [TBL] [Abstract][Full Text] [Related]
7. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha. Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634 [TBL] [Abstract][Full Text] [Related]
8. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines. Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911 [TBL] [Abstract][Full Text] [Related]
9. [Relationship between ER-α36 and Akt in PC12 cells exposed to glucose deprivation]. Liang XF; Fang C; Ma YN; Guan X; Liu Y; Han C; Liu J; Zou W Sheng Li Xue Bao; 2013 Aug; 65(4):381-8. PubMed ID: 23963069 [TBL] [Abstract][Full Text] [Related]
10. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells. Zhang X; Deng H; Wang ZY J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581 [TBL] [Abstract][Full Text] [Related]
11. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway. Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998 [TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer. Pan C; Hu Y; Li J; Wang Z; Huang J; Zhang S; Ding L PLoS One; 2014; 9(8):e104459. PubMed ID: 25127034 [TBL] [Abstract][Full Text] [Related]
13. Expression of ER-α36, a novel variant of estrogen receptor in endometrial carcinoma and its clinical significance. Sun L; Wang J; Zhang L; Li X; Shen D Gynecol Obstet Invest; 2013; 75(1):68-72. PubMed ID: 23257935 [TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor α36 mediates a bone-sparing effect of 17β-estrodiol in postmenopausal women. Xie H; Sun M; Liao XB; Yuan LQ; Sheng ZF; Meng JC; Wang D; Yu ZY; Zhang LY; Zhou HD; Luo XH; Li H; Wu XP; Wei QY; Tang SY; Wang ZY; Liao EY J Bone Miner Res; 2011 Jan; 26(1):156-68. PubMed ID: 20578216 [TBL] [Abstract][Full Text] [Related]
15. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258 [TBL] [Abstract][Full Text] [Related]
16. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Zhang XT; Kang LG; Ding L; Vranic S; Gatalica Z; Wang ZY Oncogene; 2011 Feb; 30(7):770-80. PubMed ID: 20935677 [TBL] [Abstract][Full Text] [Related]
17. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Wang Z; Zhang X; Shen P; Loggie BW; Chang Y; Deuel TF Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9063-8. PubMed ID: 16754886 [TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor variant ER-α36 is involved in estrogen neuroprotection against oxidative toxicity. Han S; Zhao B; Pan X; Song Z; Liu J; Gong Y; Wang M Neuroscience; 2015 Dec; 310():224-41. PubMed ID: 26383254 [TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer. Wang ZY; Yin L Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453 [TBL] [Abstract][Full Text] [Related]
20. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]